Skip to main content

Table 7 28-day mortality (safety population)

From: A placebo-controlled, double-blind, dose-escalation study to assess the safety, tolerability and pharmacokinetics/pharmacodynamics of single and multiple intravenous infusions of AZD9773 in patients with severe sepsis and septic shock

 

AZD9773 cohort 1

(50 U/kg)

(n= 8)

AZD9773 cohort 2

(250 U/kg)

(n= 9)

AZD9773 cohort 3

(250/50 U/kg) (n= 12)

AZD9773 cohort 4

(500/100 U/kg) (n= 10)

AZD9773 cohort 5

(750/250 U/kg)

(n= 8)

Placebo (n= 23)

Alive, n (%)

6 (75.0)

5 (55.6)

7 (58.3)

9 (90.0)

7 (87.5)

16 (69.6)

Dead, n (%)

2 (25.0)

4 (44.4)

5 (41.7)

1 (10.0)

1 (12.5)

6 (26.1)

Lost to follow-up, n (%)

0

0

0

0

0

1 (4.3)

Back to article page

Critical Care

ISSN: 1364-8535